Dexasone
Post-Operative Pain, Non-Human Animal
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
IVO JURISIC
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07084753CT.gov Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy | — | Not Yet Recruiting | — | — | — |
NCT07337135CT.gov Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery | — | Completed | — | — | — |
NCT03339284CT.gov QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery | — | Unknown | — | — | — |
NCT01116713CT.gov Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Post-Operative Pain, Non-Human Animal
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | IVO JURISIC | Approved | BB · 69 |
| Lidocaine | Instituto Mexicano del Seguro Social | P4 | BBB |
| Ropivacaine | Tianjin Medical University General Hospital | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Tanta University | P4 | BBB |
| Nepenthe | IVO JURISIC | P4 | BBB |
| Marcaine | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Fentanyl | IVO JURISIC | P4 | BB |
| Metamizole | Hospital dos Lusíadas | P4 | BB |
| Dexmedetomidine | Tanta University | P4 | BB |
+30 more in the Post-Operative Pain, Non-Human Animal cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in Post-Operative Pain, Non-Human Animal. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-post-operative-pain-non-human-animal
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →